Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010;363:1521-31. DOI: 10.1056/NEJMoa0901510.

Table 1a. **Baseline Characteristics of the Study Patients with Site 009 removed (N=421).**

	Placebo n=70	Tanezumab 10 µg/kg n=71	Tanezumab 25 µg/kg n=71	Tanezumab 50 µg/kg n=69	Tanezumab 100 µg/kg n=70	Tanezumab 200 µg/kg n=70
Age, mean (SD), years	58.3 (7.7)	58.1 (8.1)	59.8 (8.2)	60.6 (7.8)	57.1 (8.2)	58.8 (7.4)
Female, n (%)	39 (55.7)	46 (64.8)	47 (66.2)	32 (46.4)	42 (60.0)	37 (52.9)
White, n (%)	62 (88.6)	59 (83.1)	64 (90.1)	61 (88.4)	63 (90.0)	60 (85.7)
Kellgren–Lawrence X-ray grade, n (%)*****						
Grade 2	17 (24.6)	20 (28.2)	22 (30.6)	27 (40.3)	21 (30.0)	17 (25.0)
Grade 3–4	51 (73.9)	50 (70.4)	50 (69.4)	40 (59.7)	49 (70.0)	50 (73.5)
Walking knee pain, mean (SD), VAS*****	71.6 (9.8)	70.5 (11.0)	71.2 (10.4)	67.9 (10.5)	70.9 (11.2)	72.6 (11.5)
SGA, mean (SD), VAS*****	49.0 (21.0)	55.2 (20.5)	50.3 (20.5)	51.8 (16.9)	50.3 (19.7)	54.8 (23.0)
WOMAC, mean (SD), VAS*****						
Pain	69.1 (12.0)	65.7 (14.1)	68.5 (12.3)	61.7 (12.4)	68.2 (13.1)	68.7 (12.2)
Stiffness	74.4 (13.7)	70.3 (12.4)	74.7 (12.5)	66.4 (17.8)	71.4 (17.8)	73.1 (13.2)
Physical function	69.0 (12.6)	63.9 (13.7)	68.8 (14.7)	61.8 (12.3)	67.6 (14.4)	68.2 (14.3)

Kellgren–Lawrence scores: 2 (minimal) = definite osteophytes without reduction of the joint space; 3 (moderate) = joint space has diminished; 4 (severe) = greatly reduced joint space.
Knee pain range = No pain (0) to extreme pain (100).
SGA range = Very poor (0) to very good (100).
WOMAC range = No pain, no stiffness, or very good physical function (0) to extreme pain, extreme stiffness, or very poor physical function (100).

*Data for the mITT population.
SD, standard deviation; VAS, visual analog scale; SGA, Subject Global Assessment; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; mITT, modified intent-to-treat.

Table 2a. **Secondary Efficacy Endpoints with Site 009 removed (N=417).**

	Placebo n=69	Tanezumab 10 µg/kg n=71	Tanezumab 25 µg/kg n=72	Tanezumab 50 µg/kg n=67	Tanezumab 100 µg/kg n=70	Tanezumab 200 µg/kg n=68
Mean change from baseline over weeks 1–16 (SE), VAS						
WOMAC pain	–16.4 (2.4)	–30.2 (2.3)*	–37.3 (2.2)*	–28.4 (2.4)*	–38.9 (2.3)*	–43.4 (2.4)*
WOMAC stiffness	–16.7 (2.5)	–33.6 (2.3)*	–39.0 (2.3)*	–34.0 (2.5)*	–41.9 (2.3)*	–47.5 (2.4)*
WOMAC physical function	–15.3 (2.4)	–30.3 (2.3)*	–36.1 (2.2)*	–30.2 (2.4)*	–39.9 (2.3)*	–43.8 (2.4)*
OMERACT-OARSI responder rate over weeks 1–16, %	44.9	74.6*	86.1*	73.1*	92.9*	94.1*

*P<0.001 vs. placebo.
WOMAC range = No pain, no stiffness, or very good physical function (0) to extreme pain, extreme stiffness, or very poor physical function (100).
SE, standard error; VAS, visual analog scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; OMERACT-OARSI, Outcome Measures for Rheumatology Committee and Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative.

Table 3a. **Frequency of Adverse Events with Site 009 removed (N=421).**

	Placebo n=70	Tanezumab 10 µg/kg n=71	Tanezumab 25 µg/kg n=71	Tanezumab 50 µg/kg n=69	Tanezumab 100 µg/kg n=70	Tanezumab 200 µg/kg n=70
Number of patients, n (%)						
Any AE	41 (58.6)	51 (71.8)	48 (67.6)	44 (63.8)	50 (71.4)	57 (81.4)
Treatment-related AE	6 (8.6)	11 (15.5)	13 (18.3)	8 (11.6)	21 (30.0)	26 (37.1)
Any severe AE	2 (2.9)	6 (8.5)	3 (4.2)	3 (4.3)	2 (2.9)	3 (4.3)
Treatment-related severe AE	0	0	1 (1.4)	0	1 (1.4)	0
Any serious AE*	1 (1.4)	2 (2.8)	0	2 (2.9)	0	2 (2.9)
Treatment-related serious AE	0	0	0	0	0	0
AEs occurring in ≥5% of tanezumab-treated patients†						
Headache	2 (2.9)	8 (11.3)	5 (7.0)	8 (11.6)	6 (8.6)	6 (8.6)
Upper RTI	4 (5.7)	2 (2.8)	6 (8.5)	5 (7.2)	7 (10.0)	7 (10.0)
Arthralgia	0	1 (1.4)	2 (2.8)	5 (7.2)	4 (5.7)	7 (10.0)
Pain in extremity	0	3 (4.2)	1 (1.4)	2 (2.9)	6 (8.6)	9 (12.9)
Peripheral edema	2 (2.9)	0	2 (2.8)	5 (7.2)	6 (8.6)	8 (11.4)
AEs of abnormal peripheral sensation						
Allodynia	0	0	0	0	1 (1.4)	1 (1.4)

Burning sensation	1 (1.4)	0	0	0	1 (1.4)	0
Dysesthesia	0	0	0	0	1 (1.4)	1 (1.4)
Hyperesthesia	0	0	0	3 (4.3)	4 (5.7)	4 (5.7)
Hypoesthesia	0	1 (1.4)	6 (8.5)	2 (2.9)	5 (7.1)	5 (7.1)
Neuralgia	0	0	0	0	1 (1.4)	0
Neuritis	0	0	0	0	1 (1.4)	0
Pallanesthesia	0	0	1 (1.4)	0	0	1 (1.4)
Paresthesia	2 (2.9)	4 (5.6)	4 (5.6)	1 (1.4)	8 (11.4)	8 (11.4)
Sensory disturbance	0	0	0	1 (1.4)	1 (1.4)	2 (2.9)
Sensory loss	0	0	1 (1.4)	0	0	1 (1.4)

*No serious AE was considered to be treatment-related.
†All tanezumab groups combined.
AE, adverse event; RTI, respiratory tract infection.

Figure 1a. **Patient Disposition with Site 009 removed.**



***Patients could enter the OLE at week 16.**
OLE, open-label extension; AE, adverse event; mITT, modified intent-to-treat.

Figure 2a. **Change from Baseline in (A) Walking Knee Pain and (B) Subject Global Assessment with Site 009 removed (N=417).**



†P=0.001, *P<0.001 vs. placebo.
Knee pain range = No pain (0) to extreme pain (100).
SGA range = Very poor (0) to very good (100).

SGA, Subject Global Assessment; VAS, Visual Analog Scale; LS, least squares; SE, standard error.